Blood disorders
Lymphoma in Shenyang
沈阳 淋巴瘤
3 hospitals in Shenyang
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Shenyang may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 26 papers ledNo open trial led
- 11 papers ledNo open trial led
- 5 papers ledNo open trial led
Lymphoma in every city Shenyang on the disease page, with the national map
open trials on lymphoma with a hospital in Shenyang
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Shenyang as lead sponsor or study site. 0 of them are led by a hospital in Shenyang. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06742996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- RecruitingMZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06793189
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 2 listed hospitals as study sitesBeijing, Shanghai, Shenyang
- RecruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06943872
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou
- RecruitingA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06973187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou
- RecruitingA Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07124936
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07154264
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingApplication of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
- Phase
- Phase 4
- Started
- 2025-11
- Posted
- Registry
- NCT07355699
Age 18 years to Not stated (registered criteria)
Led by Beijing Tongren Hospital; 2 listed hospitals as study sitesBeijing, Shenyang
- RecruitingA Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06219356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06082102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT06084936
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou
- RecruitingEvaluate the Safety and Clinical Activity of HH2853
- Phase
- Phase 1/Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04390737
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- Not yet recruitingA Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07784101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingEvaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07187960
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Shenyang
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Central Hospital of Shenyang Medical College沈阳医学院附属中心医院 | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Hospital of Liaoning University of Traditional Chinese Medicine辽宁中医药大学附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 21 open | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | |
| China Shenyang Chest Hospital沈阳市胸科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fifth People Hospital沈阳市第五人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Hospital of China Medical University中国医科大学附属第一医院 | 5 | 7 | 612 open | 1091 open | 1514 open | 46 | 1301 open | 53 | none | none | 0 | 5 | 6 | 2 | 1 | 4 | 0 | none | 2 | 26 | none | 1 | none | 0 | none | 6 | 6 | 9 | none | none | none | 17 | 51 open | none | 2 | 0 | none | 3 | none | 3 | none | 0 | none | 1 | none | none | 4 | none | none | 1 | 1 | 2 | none | none | 1 | 0 | none | none | none | none | none | |
| Fourth Affiliated Hospital of China Medical University中国医科大学附属第四医院 | none | none | 11 | 20 | 18 | 8 | none | none | none | none | none | 2 | none | 2 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| General Hospital, China Medical University中国人民解放军北部战区总医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Liaoning Cancer Hospital & Institute辽宁省肿瘤医院 | none | 9 | 16 | 402 open | 602 open | 6 | 751 open | 21 | none | none | none | 11 | 2 | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Northern Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| People's Hospital, China Medical University辽宁省人民医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine辽宁中医药大学附属第二医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shengjing Hospital of China Medical University中国医科大学附属盛京医院 | 5 | none | 601 open | 27 | 991 open | 522 open | 6319 open | 471 open | 0 | 2 | none | 25 | 6 | 10 | 1 | 7 | none | none | none | 11 | none | 0 | 0 | 0 | none | 2 | 3 | 4 | none | 2 | 4 | 21 | 23 | 2 | none | 1 | none | 5 | none | 2 | 0 | none | 0 | 1 | 1 | none | 4 | none | none | 1 | 0 | 1 | 0 | 0 | none | none | none | none | none | none | none | |
| Shenyang Northern Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 04 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Shenyang.
- Nasopharyngeal carcinoma 5
- Oesophageal squamous cell carcinoma 7
- Hepatocellular carcinoma 612 open
- Stomach cancer 1091 open
- Lung cancer 1514 open
- Pancreatic cancer 46
- Breast cancer 1301 open
- Glioma 53
- Chordoma 0
- Osteosarcoma 5
- Gastrointestinal stromal tumour 6
- Neuroblastoma 2
- Ewing sarcoma 1
- Multiple myeloma 4
- B-cell acute lymphoblastic leukaemia 0
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 26
- Haemophilia A 1
- Thrombotic thrombocytopenic purpura 0
- Neuromyelitis optica spectrum disorder 6
- IgG4-related disease 6
- Myasthenia gravis 9
- Coronary heart disease 17
- Congenital heart disease 51 open
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 3
- Amyotrophic lateral sclerosis 3
- Fabry disease 0
- Duchenne muscular dystrophy 1
- IgA nephropathy 4
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 2
- Inherited epidermolysis bullosa 1
- Hereditary angioedema 0
- Nasopharyngeal carcinoma 5
- Hepatocellular carcinoma 601 open
- Stomach cancer 27
- Lung cancer 991 open
- Pancreatic cancer 522 open
- Breast cancer 6319 open
- Glioma 471 open
- Hepatoblastoma 0
- Retinoblastoma 2
- Osteosarcoma 25
- Gastrointestinal stromal tumour 6
- Neuroblastoma 10
- Ewing sarcoma 1
- Multiple myeloma 7
- Lymphoma 11
- Haemophilia A 0
- Atypical haemolytic uraemic syndrome 0
- Thrombotic thrombocytopenic purpura 0
- Neuromyelitis optica spectrum disorder 2
- IgG4-related disease 3
- Myasthenia gravis 4
- Wilson disease 2
- Biliary atresia 4
- Coronary heart disease 21
- Congenital heart disease 23
- Scoliosis 2
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 5
- Amyotrophic lateral sclerosis 2
- Spinal muscular atrophy 0
- Pompe disease 0
- Duchenne muscular dystrophy 1
- Behçet disease 1
- IgA nephropathy 4
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 1
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 0
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Shenyang on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.